PURLs

How old is too old for statins?

Author and Disclosure Information

 

References

CAVEATS

Retrospective cohort design leaves cause and effect equivocal

Even though the first study was large (with more than 46,000 patients) and the median follow-up was 5.6 years, it was a retrospective cohort study. While there is clearly an association between statin therapy and reduced ASCVD and all-cause mortality in patients with diabetes ages 75 to 84 years, cause and effect cannot be unequivocally stated. However, the meta-analysis, which included RCTs, confirms the benefit of statins in secondary prevention for older patients.

The cohort study did not look at adverse effects from statin therapy in this age group, but the data from the 2019 meta-analysis did not reveal any significant risk of myopathy.

CHALLENGES TO IMPLEMENTATION

Guidelines are lacking and discontinuing meds requires discussion

The lack of supporting guidelines to treat this age group with statins remains the largest barrier to implementation. Many patients may already be taking a statin, so a discussion about discontinuing medication will need to be initiated.

ACKNOWLEDGMENT

The PURLs Surveillance System was supported in part by Grant Number UL1RR024999 from the National Center For Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Research Resources or the National Institutes of Health.

Pages

Copyright © 2020. The Family Physicians Inquiries Network. All rights reserved.

Online-Only Materials

AttachmentSize
PDF icon jfp06906257_methodology.pdf162.95 KB

Recommended Reading

Low fitness level linked to higher risk of heart failure in diabetes
Type 2 Diabetes ICYMI
Larger absolute rivaroxaban benefit in diabetes: COMPASS
Type 2 Diabetes ICYMI
Dapagliflozin trial in CKD halted because of high efficacy
Type 2 Diabetes ICYMI
Enhanced team-based CVD care found to benefit diabetes patients
Type 2 Diabetes ICYMI
AHA updates management when CAD and T2DM coincide
Type 2 Diabetes ICYMI
COVID-19 cases highlight longstanding racial disparities in health care
Type 2 Diabetes ICYMI
SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit
Type 2 Diabetes ICYMI
New study of diabetes drug for COVID-19 raises eyebrows
Type 2 Diabetes ICYMI
FDA approves dapagliflozin for low-EF heart failure
Type 2 Diabetes ICYMI
Adolescent obesity, diabetes linked to atherosclerotic signs
Type 2 Diabetes ICYMI